This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

American Shared Hospital Services Shares Developments At Mevion Medical Systems

Stocks in this article: AMS

AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, developer of the MEVION S250 Proton Therapy System for cancer treatment. AMS owns an equity interest in Mevion, and will supply a MEVION S250 for the proton center now under construction at MD Anderson Cancer Center in Orlando, in addition to other projects under development:

MEVION S250 at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Moves to Clinical Commissioning

Littleton, MA, September 22nd, 2013 -- Today, Mevion Medical Systems announced moving from acceptance testing to the clinical commissioning phase of its MEVION S250 Proton Therapy System installed at the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO. The MEVION S250 is a unique proton therapy device designed to deliver the same precise, non-invasive treatment capabilities and advantages of conventional systems but with a significantly reduced size, improved reliability, efficient clinical workflow and lower implementation and operational costs. This important milestone marks the handover and operational control of the first MEVION S250 to the physics and radiation oncology proton teams from the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine for clinical commissioning and patient treatment.

Acceptance testing is a series of demanding tests designed to independently put the MEVION S250 through its paces, carefully validating that technical and clinical performance specifications are met and that the system is ready for clinical commissioning. The Washington University physics team led by Eric E. Klein, PhD, chief of proton therapy physics, performed these tests over a three-month period. "The results of our testing confirm that the MEVION S250 is ready to move into the clinical commissioning phase," said Dr. Klein. "We are excited to be in final clinical preparation for our first patient treatment later this year," added Jeffrey D. Bradley, MD, Washington University radiation oncologist and director of the S. Lee Kling Center for Proton Therapy.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs